Aggressive mammary carcinoma progression in Nrf2 knockout mice treated with 7,12-dimethylbenz[a]anthracene

BMC Cancer

Table 2 Incidence of lesions in Nrf2 mammary tumor study

Lesion	WT-% inc	KO-% inc	p-value
Mammary region
Hyperplasia	55.9 ± 0.5	46.7 ± 0.5
Pm (DCIS, early Ca)	67.6 ± 0.5	63.3 ± 0.5
Mam. carcinoma	58.8 ± 0.5	66.7 ± 0.5
Sebaceous	2.9 ± 0.2	3.3 ± 0.2
Adenoacanthoma	5.9 ± 0.2	20.0 ± 0.4	0.091
Lung mets (mc)	5.9 ± 0.2	6.7 ± 0.2
Sarcoma	8.8 ± 0.3	3.3 ± 0.2
Other (fibroadenoma, cyst)	8.8 ± 0.3	13.3 ± 0.3
Lymphomas (by location)
Lung	23.5 ± 0.4	16.7 ± 0.4
Spleen	32.4 ± 0.5**	10.0 ± 0.3	0.031
Liver	29.4 ± 0.5	16.7 ± 0.4
Mediastinal mass	35.3 ± 0.5	20.0 ± 0.4
Mammary gland	11.8 ± 0.3	6.7 ± 0.2
Lymph node	0	6.7 ± 0.2
Other (internal mass, bone)	0	10.0 ± 0.3
Mice with any lymphoma	47.1 ± 0.5	36.7 ± 0.5
Any high-grade lymphoma	20.6 ± 0.4**	3.3 ± 0.2	0.042
Other lesions
Lung adenomas	17.6 ± 0.4**	46.7 ± 0.5	0.012
Skin pap/carc	26.5 ± 0.5	10.0 ± 0.3	0.095
Liver steatosis	23.5 ± 0.4**	3.3 ± 0.2	0.020
Ovarian sex cord stromal	11.8 ± 0.3	6.7 ± 0.2

Values represent the mean incidence (% Inc.) of lesions ± SD (n = 34 WT, 30 KO). ** Significantly different from KO mice, p ≤ 0.05. Pm, premalignant lesions, mc, mammary carcinoma. P-values are shown for differences that were either significant (p ≤ 0.05) or marginally significant (p ≤ 0.1).

ISSN: 1471-2407